The effects of coenzyme Q10 on cerebral infarctio
Phase 3
Recruiting
- Conditions
- Ischemic stroke.Cerebral infarction
- Registration Number
- IRCT20210907052400N2
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Patients with acute ischemic stroke
Patients who have had a stroke for the first time
Patients between the ages of 20 and 80
Exclusion Criteria
Having other neurodegenerative disorders
Having acute mental disorders
Having liver and kidney malignancies
Having rheumatism and chronic infections
Taking vitamin supplements and immune boosters in the last month
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Oxidative stress. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Spectroscopy (by taking a blood sample).;Sensory-motor function. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Using Berg Balance Scale.;Psycho-cognitive function. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Using the MoCA questionnaire.;Physical activity rate. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Using SIMPAQ questionnaire and Barthel index.
- Secondary Outcome Measures
Name Time Method